Clinical Trial

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
Trial Details
NCT Number NCT07705555
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diabetic Retinopathy, Macular Edema
Enrollment 960 participants
Start Date 2026-08-28
Primary Completion 2028-10-31 (estimated)
Study Completion 2029-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15